MetaCap

Braveheart Bio (BRVE) vs Korsana Biosciences (KRSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korsana Biosciences is the larger company by market cap ($1.71 billion vs $1.67 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BRVE-31.58%KRSA+50.72%
+55%+5%-46%
Aug 6, 20261 yearNov 20, 2026
BRVE-32.03%KRSA+50.30%
+55%+6%-42%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BRVE versus KRSA key metrics
MetricBRVEKRSA
Share price$20.39$37.56
Market cap$1.67B$1.71B
1-day change+5.81%+5.95%
YTD return—+322.50%
1-year return—+262.55%
5-year return—-89.05%
EPS (TTM)$-6.59$-16.14
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.07M
Revenue growth (YoY)—+3.70%
Net income (latest FY)—$-3.53M
Operating margin—-239.78%
Net margin—-170.11%
52-week high$32.00$59.36
52-week low$16.70$7.19
Distance from 52-week high-36.28%-36.73%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+123.15%+17.15%
Average volume491.27K119.71K
Shares outstanding82.07M45.54M
Employees4919
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Braveheart Bio

BRVE stock →

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Korsana Biosciences

KRSA stock →

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

BRVE vs KRSA FAQ

Which is bigger, Braveheart Bio or Korsana Biosciences?

Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.71B compared with $1.67B for Braveheart Bio (BRVE).

Are Braveheart Bio and Korsana Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons